Chiasma, Inc. (CHMA) Sees Large Decline in Short Interest

Chiasma, Inc. (NASDAQ:CHMA) was the target of a large drop in short interest during the month of September. As of September 29th, there was short interest totalling 442,548 shares, a drop of 35.1% from the September 15th total of 681,631 shares. Based on an average daily volume of 85,511 shares, the short-interest ratio is currently 5.2 days. Currently, 3.7% of the company’s shares are sold short.

Chiasma (CHMA) opened at 2.45 on Wednesday. The company’s market capitalization is $59.68 million. The firm’s 50-day moving average price is $2.53 and its 200 day moving average price is $2.53. Chiasma has a 12-month low of $1.25 and a 12-month high of $2.95.

In other Chiasma news, Director Scott Minick bought 25,000 shares of Chiasma stock in a transaction on Thursday, September 21st. The shares were purchased at an average cost of $2.37 per share, for a total transaction of $59,250.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.80% of the stock is owned by company insiders.

Separately, ValuEngine upgraded Chiasma from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.

WARNING: “Chiasma, Inc. (CHMA) Sees Large Decline in Short Interest” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2966962/chiasma-inc-chma-sees-large-decline-in-short-interest.html.

Chiasma Company Profile

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.